MX2021000941A - Compuestos de pirimidina y composiciones farmaceuticas para prevenir o tratar canceres que incluyen los mismos. - Google Patents

Compuestos de pirimidina y composiciones farmaceuticas para prevenir o tratar canceres que incluyen los mismos.

Info

Publication number
MX2021000941A
MX2021000941A MX2021000941A MX2021000941A MX2021000941A MX 2021000941 A MX2021000941 A MX 2021000941A MX 2021000941 A MX2021000941 A MX 2021000941A MX 2021000941 A MX2021000941 A MX 2021000941A MX 2021000941 A MX2021000941 A MX 2021000941A
Authority
MX
Mexico
Prior art keywords
preventing
same
pharmaceutical compositions
cancers including
treating cancers
Prior art date
Application number
MX2021000941A
Other languages
English (en)
Inventor
Seok Jong Kang
In Hwan Bae
Young Gil Ahn
Ji Sook Kim
Jae Yul Choi
Kween Hyun SUH
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Publication of MX2021000941A publication Critical patent/MX2021000941A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se proporcionan un compuesto de pirimidina representado por la Fórmula 1, un método para preparar el compuesto, y un uso farmacéutico del compuesto para la prevención o el tratamiento del cáncer.
MX2021000941A 2018-07-25 2019-02-13 Compuestos de pirimidina y composiciones farmaceuticas para prevenir o tratar canceres que incluyen los mismos. MX2021000941A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020180086768A KR101954370B1 (ko) 2018-07-25 2018-07-25 피리미딘 화합물 및 이를 포함하는 암의 예방 또는 치료용 약학 조성물
PCT/KR2019/001737 WO2020022600A1 (en) 2018-07-25 2019-02-13 Pyrimidine compounds and pharmaceutical compositions for preventing or treating cancers including the same

Publications (1)

Publication Number Publication Date
MX2021000941A true MX2021000941A (es) 2021-03-09

Family

ID=65760263

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021000941A MX2021000941A (es) 2018-07-25 2019-02-13 Compuestos de pirimidina y composiciones farmaceuticas para prevenir o tratar canceres que incluyen los mismos.

Country Status (17)

Country Link
US (2) US11292786B2 (es)
EP (1) EP3810601A4 (es)
JP (1) JP6806931B2 (es)
KR (1) KR101954370B1 (es)
CN (2) CN116693506A (es)
AR (1) AR119657A1 (es)
BR (1) BR112021001122A2 (es)
CA (1) CA3106961A1 (es)
CL (1) CL2021000175A1 (es)
DO (1) DOP2021000017A (es)
MX (1) MX2021000941A (es)
PE (1) PE20210373A1 (es)
PH (1) PH12021550124A1 (es)
SG (1) SG11202100076RA (es)
TW (1) TWI839363B (es)
WO (1) WO2020022600A1 (es)
ZA (1) ZA202100485B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220110913A1 (en) * 2019-02-22 2022-04-14 Hanmi Pharm. Co., Ltd Pharmaceutical composition comprising flt3 inhibitor and hypomethylating agent for treating acute myeloid leukemia
MX2021015724A (es) * 2019-06-27 2022-05-16 Hanmi Pharm Ind Co Ltd Composición farmacéutica para el tratamiento de la leucemia mieloide aguda, que contiene inhibidores de flt3 y agentes quimioterapéuticos.
KR20210038366A (ko) * 2019-09-30 2021-04-07 한미약품 주식회사 Flt3 저해제 및 mdm2 저해제를 포함하는 급성 골수성 백혈병 치료용 약학적 조성물
WO2022098083A1 (ko) * 2020-11-05 2022-05-12 한미약품 주식회사 Flt3 억제제를 포함하는 백혈병 치료용 약학적 조성물
TW202246243A (zh) * 2021-02-26 2022-12-01 美商泰拉生物科學公司 胺基嘧啶化合物及其使用方法
KR102666918B1 (ko) * 2021-04-08 2024-05-20 주식회사 스탠다임 신규한 lrrk2 억제제
WO2023027966A1 (en) 2021-08-24 2023-03-02 Biomea Fusion, Inc. Pyrazine compounds as irreversible inhibitors of flt3
KR20230056331A (ko) * 2021-10-20 2023-04-27 한미약품 주식회사 급성 골수성 백혈병의 치료를 위한 FLT3 저해제와 Bcl-2 저해제의 치료 유효적 조합
EP4370506A1 (en) 2021-12-30 2024-05-22 Biomea Fusion, Inc. Pyrazine compounds as inhibitors of flt3
WO2023225005A1 (en) 2022-05-17 2023-11-23 Biomea Fusion, Inc. Flt3 combination therapy for cancer and compositions therefor

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0500492D0 (en) 2005-01-11 2005-02-16 Cyclacel Ltd Compound
EP2212293A4 (en) * 2007-10-24 2010-12-01 Merck Sharp & Dohme ANTAGONISTS OF T-TYPE CALCIUM CHANNELS BASED ON HETEROCYCLIC AMIDE
FR2926553B1 (fr) * 2008-01-23 2010-02-19 Sanofi Aventis Derives d'indole-2-carboxamides et d'azaindole-2- carboxamides substitues par un groupe silanyle, leur preparation et leur application en therapeutique
US20110183975A1 (en) * 2008-10-07 2011-07-28 Yasuhiro Goto Novel 6-azaindole aminopyrimidine derivatives having nik inhibitory activity
US8435980B2 (en) * 2009-07-15 2013-05-07 Abbvie Inc. Pyrrolopyridine inhibitors of kinases
SG186378A1 (en) * 2010-06-23 2013-01-30 Hanmi Science Co Ltd Novel fused pyrimidine derivatives for inhibition of tyrosine kinase activity
UY33539A (es) * 2010-08-02 2012-02-29 Astrazeneca Ab Compuestos químicos alk
WO2014155300A2 (en) * 2013-03-28 2014-10-02 Aurigene Discovery Technologies Limited Substitued pyrimidine amine derivatives as tak-1 inhibitors
KR20170003553A (ko) * 2014-04-04 2017-01-09 사이로스 파마수티컬스, 인크. 사이클린-의존성 키나제 7(cdk7)의 저해제
ES2805976T3 (es) 2016-06-30 2021-02-16 Janssen Pharmaceutica Nv Derivados heteroaromáticos en calidad de inhibidores de NIK
BR112019015256A2 (pt) * 2017-01-26 2020-04-14 Hanmi Pharm Ind Co Ltd composto selecionado de uma substância de fórmula 1 e um sal farmaceuticamente aceitável da mesma, e composicão farmacêutica

Also Published As

Publication number Publication date
EP3810601A4 (en) 2022-04-20
PH12021550124A1 (en) 2021-09-27
US20230002358A1 (en) 2023-01-05
CL2021000175A1 (es) 2021-07-02
KR101954370B1 (ko) 2019-03-05
CN116693506A (zh) 2023-09-05
EP3810601A1 (en) 2021-04-28
CN112469715A (zh) 2021-03-09
PE20210373A1 (es) 2021-02-26
JP6806931B2 (ja) 2021-01-06
US11292786B2 (en) 2022-04-05
BR112021001122A2 (pt) 2021-04-13
WO2020022600A1 (en) 2020-01-30
SG11202100076RA (en) 2021-02-25
DOP2021000017A (es) 2021-04-15
CN112469715B (zh) 2024-06-11
ZA202100485B (en) 2023-11-29
AR119657A1 (es) 2022-01-05
TWI839363B (zh) 2024-04-21
TW202014417A (zh) 2020-04-16
JP2020527128A (ja) 2020-09-03
US20200255410A1 (en) 2020-08-13
CA3106961A1 (en) 2020-01-30

Similar Documents

Publication Publication Date Title
ZA202100485B (en) Pyrimidine compounds and pharmaceutical compositions for preventing or treating cancers including the same
SA519402288B1 (ar) مركب بيريميدين واستخداماته الصيدلانية
EA202091491A1 (ru) Новые бензиламинозамещенные пиридопиримидиноны и производные в качестве ингибиторов sos1
MX2020011907A (es) Inhibidores de kras g12c para el tratamiento de cancer.
MX2020007485A (es) Compuestos antiproliferativos y metodos de uso de los mismos.
NZ746554A (en) Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith
MX2021014531A (es) Compuestos de aminopurina sustituida, composiciones del mismo, y metodos de tratamiento con los mismos.
MX2019003887A (es) Compuestos, dispositivos y usos de los mismos.
GEP20207161B (en) New (hetero)aryl-substituted-piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them
GEP20207160B (en) New piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them
GEP20217211B (en) Substituted carbonucleoside derivatives useful as anticancer agents
GEP20207126B (en) New ammonium derivatives, a process for their preparation and pharmaceutical compositions containing them
MX2023000025A (es) Inhibidores de la quinasa progenitora hematopoyética 1 y usos de estos.
MX2023008954A (es) Inhibidores de los receptores erbb.
IL290177A (en) History of 4,2,1-oxadiazol-5-one for cancer therapy
MX2020005659A (es) Uso de un inhibidor de parp en el tratamiento del cancer de ovario o cancer de mama resistente a la quimioterapia.
CY1121884T1 (el) Αντι-ογκικες ενωσεις
ZA202006071B (en) Antiproliferation compounds and uses thereof
MX2021012096A (es) Compuestos de indenilo, composiciones farmaceuticas y usos medicos del mismo.
MX2020012291A (es) Compuestos para el tratamiento de cancer de mama triple negativo y cancer de ovario.
MX2021012105A (es) Compuestos de pirrol.
ZA202204442B (en) Salt forms of a complement component c5a receptor
WO2019036417A3 (en) Inhibition of ngly1 for the treatment of cancer
MX2021009717A (es) Sulfonamidas biciclicas.
MX2019000542A (es) Derivados de pirazolilaminobenzimidazol como inhibidores de jak.